Loading…
Loading…
TKNO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TKNO and 80,000+ other tickers.
See exactly how TKNO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TKNO and 80,000+ other tickers.
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents…
Alpha Teknova NASDAQ: TKNO Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve.
Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.
The mean of analysts' price targets for Alpha Teknova (TKNO) points to a 35.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Alpha Teknova NASDAQ: TKNO reported second-quarter revenue growth of 18% from a year earlier, surpassing $12 million for its highest quarterly revenue in the company's 30-year history. The company raised its full-year revenue outlook, citing first-half performance and confidence in the second half of 2026.
Alpha Teknova, Inc. (TKNO) Q2 2026 Earnings Call Transcript